Results 41 to 50 of about 225,520 (261)

Trends in atrial flutter and atrial tachycardia research

open access: yesInformatics in Medicine Unlocked, 2017
Background: Atrial flutter and atrial tachycardia are frequently observed arrhythmias that can be difficult to treat effectively with catheter ablation. It would be of interest to know the research directions for these arrhythmias in order to plan future
Edward J. Ciaccio   +3 more
doaj   +1 more source

Transcatheter Tricuspid Valve Replacement for Residual Tricuspid Regurgitation After TEER

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Residual or recurrent tricuspid regurgitation (TR) after prior transcatheter tricuspid edge‐to‐edge (T‐TEER) repair occurs in about 12% of patients within 1 year. Since surgical tricuspid valve repair or replacement is of high risk, treatment options remain scarce.
Fabian Voß   +14 more
wiley   +1 more source

Atrial flutter: from ECG to electroanatomical 3D mapping

open access: yesHeart International, 2009
Atrial flutter is a common arrhythmia that may cause significant symptoms, including palpitations, dyspnea, chest pain and even syncope. Frequently it’s possible to diagnose atrial flutter with a 12-lead surface ECG, looking for distinctive waves in ...
Livio Dei Cas   +6 more
doaj   +1 more source

An Approach to Catheter Ablation of Cavotricuspid Isthmus Dependent Atrial Flutter [PDF]

open access: yes, 2006
Much of our understanding of the mechanisms of macro re-entrant atrial tachycardia comes from study of cavotricuspid isthmus (CTI) dependent atrial flutter.
Jönsson, Anders   +33 more
core  

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta   +5 more
wiley   +1 more source

Flutter prediction, suppression and control in aircraft composite wings as a design prerequisite: a survey [PDF]

open access: yes, 2007
Emergence of flutter compromises not only the long-term durability of the wing structure, but also the operational safety, flight performance and energy efficiency of the aircraft. Effectual means of flutter prevention are, therefore, mandatory in the
Njuguna, James A. K.
core   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen   +4 more
wiley   +1 more source

Isthmus Dependent Atrial Flutter Cycle Length Correlates with Right Atrial Cross-Sectional Area

open access: yesIndian Pacing and Electrophysiology Journal, 2009
Background: Right atrial flutter cycle length can prolong in the presence of antiarrhythmic drug therapy. We hypothesized that the cycle length of right atrial isthmus dependent flutter would correlate with right atrial cross-sectional area measurements.
Kousik Krishnan   +6 more
doaj  

Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic beta-adrenoceptor blockade [PDF]

open access: yes, 2003
<b>1.</b> 5-Hydroxytryptamine (5-HT) has been postulated to play a proarrhythmic role in the human atria via stimulation of 5-HT<sub>4</sub> receptors.
Kane, K.A.   +3 more
core   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy